SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-007005
Filing Date
2022-03-23
Accepted
2022-03-23 16:31:09
Documents
14
Period of Report
2022-03-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20220322_8k.htm   iXBRL 8-K 26080
2 EXHIBIT 99.1 ex_350027.htm EX-99.1 111939
  Complete submission text file 0001437749-22-007005.txt   281741

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20220323.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20220323_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20220323_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20220323_pre.xml EX-101.PRE 11688
8 EXTRACTED XBRL INSTANCE DOCUMENT navb20220322_8k_htm.xml XML 2570
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 22763574
SIC: 2835 In Vitro & In Vivo Diagnostic Substances